A Phase 3 interventional study of Risperidone and Ziprasidone in Schizophrenia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients
3,470 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.
This study's enrollment of 242 is above the median of 70 across 2,871 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 431 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Risperidone
Drug: Ziprasidone
Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score
Time frame: Week 6
Adverse events, laboratory test changes, movement disorder scale scores
Time frame: Weeks 1, 2, 4, and 6
Change from baseline in PANSS negative subscale score
Time frame: Weeks 1, 2, 4, and 6
Change from baseline in PANSS general psychopathology subscale score
Time frame: Weeks 1, 2, 4, and 6
PANSS responder rate
Time frame: Weeks 1, 2, 4 and 6
Clinical Global Impression-Severity (CGI-S) score
Time frame: Baseline and Weeks 1, 2, 4, and 6
Change from baseline in Brief Psychiatric Rating Scale derived (BPRSd) score
Time frame: Weeks 1, 2, 4, and 6
Change from baseline in PANSS positive subscale score
Time frame: Weeks 1, 2, 4, and 6
Clinical Global Impression-Improement (CGI-I) score
Time frame: Weeks 1, 2, 4, and 6
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.